A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new experimental pill called MOMA-313, either by itself or with an existing drug called a PARP inhibitor. Researchers want to see if this combination can safely and effectively help treat patients whose cancers have specific genetic issues with DNA repair.
This trial is for adults 18 or older with advanced or spreading solid tumors, such as breast, ovarian, prostate, or pancreatic cancer. You must have specific genetic changes in your tumor known as 'HR-deficiency' and be able to manage your daily activities independently.
Participants will receive the medication orally and undergo regular check-ups, scans, and tests to see how the body handles the drug and how the tumor responds. Since this is an early-phase trial, the primary goals are to find the right dosage and ensure the treatment is safe for patients.
The study is currently recruiting patients at medical centers in Goodyear, Arizona, and La Jolla and San Francisco, California. Because it is a clinical trial, you would be closely monitored by a specialized research team throughout your participation.
- 1Tests a new approach for cancers that have trouble repairing their own DNA.
- 2Participation involves taking an experimental oral medication, sometimes combined with a standard drug.
- 3Strict safety criteria apply, including evaluations of your heart health and current infections.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.